Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Analyst Ratings
Strong Buy
11 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GKOS Stock 12 Month Forecast
Average Price Target
$119.30
▲(9.22% Upside)
| Highest Price Target$165.00 | Average Price Target$119.30 | Lowest Price Target$72.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$113→$125
Buy
14.44%
Upside
Reiterated
12/12/25
Needham
$117→$125
Buy
14.44%
Upside
Reiterated
12/09/25
Positive Outlook for Glaukos: Buy Rating Reinforced by Epioxa's Market Potential and Increased Price TargetWe had calls with three doctors including two using Photrexa who are looking at starting Epioxa and one who is doing off-label Epi-On. While securing Epioxa coverage is no small task, in our view, we come away more positive on GKOS given 1) there likely is near-term upside to Photrexa numbers given no evidence of "warehousing", 2) Epioxa could increase doctors' capacity, enabling them to potentially treat more patients, and 3) assuming coverage is broadly established, Epioxa could be adopted by doctors currently doing off-label Epi-On procedures. Inside, we provide key highlights along with commentary on IOLs and MIGS. We have updated our GKOS model to include Epioxa and raise our price target to $125.
Stifel Nicolaus
$115
Buy
5.28%
Upside
Reiterated
11/24/25
Truist Financial
―
Buy
―
Reiterated
11/13/25
Piper Sandler
$165
Buy
51.06%
Upside
Reiterated
11/13/25
Wells Fargo
$122
Buy
11.69%
Upside
Reiterated
11/13/25
Jefferies
$130
Buy
19.01%
Upside
Reiterated
11/13/25
J.P. Morgan
$110→$120
Buy
9.86%
Upside
Reiterated
10/30/25
William Blair
―
Buy
―
Reiterated
10/30/25
BTIG
$104→$116
Buy
6.20%
Upside
Reiterated
10/30/25
Morgan Stanley
$72
Sell
-34.08%
Downside
Reiterated
10/29/25
Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation ConcernsWe get the mechanisms, but continue to struggle to really understand the iDose pricing longer- term. Either way, with the stock having traded off heavily recently, and an undoubtedly solid print, we'd expect a strong inflection upwards tomorrow. Key takes from the call: CAC meeting, Epioxa, and core stent business 1) Thoughts on the CAC Meeting: Investor focus heading into the print centered on the upcoming Contractor Advisory Committee (CAC) 12, where five MACs are scheduled to discuss future coverage plans for iDose, potentially in combination with other MIGS. We note that the meeting is being held by the same five MACs that issued an LCD last November that rendered combo- Morgan Stanley & Co.
Goldman Sachs
$103
Buy
-5.70%
Downside
Initiated
10/01/25
Mizuho Securities
$150→$130
Buy
19.01%
Upside
Reiterated
07/31/25
UBS
$125→$134
Buy
22.68%
Upside
Reiterated
07/31/25
Stephens
$140→$115
Buy
5.28%
Upside
Reiterated
05/02/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$113→$125
Buy
14.44%
Upside
Reiterated
12/12/25
Needham
$117→$125
Buy
14.44%
Upside
Reiterated
12/09/25
Positive Outlook for Glaukos: Buy Rating Reinforced by Epioxa's Market Potential and Increased Price TargetWe had calls with three doctors including two using Photrexa who are looking at starting Epioxa and one who is doing off-label Epi-On. While securing Epioxa coverage is no small task, in our view, we come away more positive on GKOS given 1) there likely is near-term upside to Photrexa numbers given no evidence of "warehousing", 2) Epioxa could increase doctors' capacity, enabling them to potentially treat more patients, and 3) assuming coverage is broadly established, Epioxa could be adopted by doctors currently doing off-label Epi-On procedures. Inside, we provide key highlights along with commentary on IOLs and MIGS. We have updated our GKOS model to include Epioxa and raise our price target to $125.
Stifel Nicolaus
$115
Buy
5.28%
Upside
Reiterated
11/24/25
Truist Financial
―
Buy
―
Reiterated
11/13/25
Piper Sandler
$165
Buy
51.06%
Upside
Reiterated
11/13/25
Wells Fargo
$122
Buy
11.69%
Upside
Reiterated
11/13/25
Jefferies
$130
Buy
19.01%
Upside
Reiterated
11/13/25
J.P. Morgan
$110→$120
Buy
9.86%
Upside
Reiterated
10/30/25
William Blair
―
Buy
―
Reiterated
10/30/25
BTIG
$104→$116
Buy
6.20%
Upside
Reiterated
10/30/25
Morgan Stanley
$72
Sell
-34.08%
Downside
Reiterated
10/29/25
Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation ConcernsWe get the mechanisms, but continue to struggle to really understand the iDose pricing longer- term. Either way, with the stock having traded off heavily recently, and an undoubtedly solid print, we'd expect a strong inflection upwards tomorrow. Key takes from the call: CAC meeting, Epioxa, and core stent business 1) Thoughts on the CAC Meeting: Investor focus heading into the print centered on the upcoming Contractor Advisory Committee (CAC) 12, where five MACs are scheduled to discuss future coverage plans for iDose, potentially in combination with other MIGS. We note that the meeting is being held by the same five MACs that issued an LCD last November that rendered combo- Morgan Stanley & Co.
Goldman Sachs
$103
Buy
-5.70%
Downside
Initiated
10/01/25
Mizuho Securities
$150→$130
Buy
19.01%
Upside
Reiterated
07/31/25
UBS
$125→$134
Buy
22.68%
Upside
Reiterated
07/31/25
Stephens
$140→$115
Buy
5.28%
Upside
Reiterated
05/02/25
Best Analysts Covering Glaukos
1 Month
xxx
Success Rate
11/12 ratings generated profit
Average Return
+7.95%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 91.67% of your transactions generating a profit, with an average return of +7.95% per trade.
3 Months
xxx
Success Rate
10/12 ratings generated profit
Average Return
+6.47%
reiterated a xxx
rating 30 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +6.47% per trade.
1 Year
Success Rate
10/13 ratings generated profit
Average Return
+16.12%
reiterated a buy rating 16 hours ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +16.12% per trade.
2 Years
xxx
Success Rate
15/19 ratings generated profit
Average Return
+49.36%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +49.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GKOS Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
5
5
5
4
Buy
15
14
18
23
21
Hold
11
9
10
6
5
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
31
28
34
35
31
Each month's total comprises the sum of three months' worth of ratings.
GKOS Financial Forecast
GKOS Stock Forecast FAQ
What is GKOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Glaukos’s 12-month average price target is 119.30.
What is GKOS’s upside potential, based on the analysts’ average price target?
Glaukos has 9.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GKOS a Buy, Sell or Hold?
Glaukos has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 1 sell ratings.
What is Glaukos’s price target?
The average price target for Glaukos is 119.30. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $165.00 ,the lowest forecast is $72.00. The average price target represents 9.22% Increase from the current price of $109.23.
The highest analyst price target is $165.00 ,the lowest forecast is $72.00. The average price target represents 9.22% Increase from the current price of $109.23.
What do analysts say about Glaukos?
Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of GKOS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.